Loading...
Loading...
A report from Oppenheimer reiterates it Outperform rating and lowers it price target from $70 to $57 on DeVry
DV.
The report states, “September total enrollment decreased 0.9% y/y. Despite DeVry Undergrad & Carrington concerns, positive growth in enrollment occurred at all currently reporting segments, with DeVry Graduate total enrollment +2% y/y, DeVry Medical (Ross/AUC aggregate) new/total enrollments +23%+6% y/y, and DeVry Brasil new/total enrollments +29%/+18% y/y. We anticipate Chamberlain growth to remain solid."
DV closed yesterday at $46.08.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in